HEREDITARY ANGIOEDEMA (HAE)
Clinical trials for HEREDITARY ANGIOEDEMA (HAE) explained in plain language.
Never miss a new study
Get alerted when new HEREDITARY ANGIOEDEMA (HAE) trials appear
Sign up with your email to follow new studies for HEREDITARY ANGIOEDEMA (HAE), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Long-Term control of rare swelling disorder
Disease control ENROLLING_BY_INVITATIONThis study aims to evaluate the long-term safety and effectiveness of navenibart for people with hereditary angioedema (HAE), a rare condition causing sudden, severe swelling. The trial involves 145 adults and adolescents who previously participated in an earlier study of the sam…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Phase: PHASE3 • Sponsor: Astria Therapeutics, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Tracking a rare disease Drug's Real-World impact
Disease control OngoingThis study is observing 50 patients in the UK who have hereditary angioedema (HAE) and are taking the drug lanadelumab as part of their normal care. The main goal is to compare how many HAE attacks patients experience in the year before starting the drug to the number they have i…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Sponsor: Takeda • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New drug trial aims to tame rare swelling disorder
Disease control OngoingThis study is testing an investigational drug called BW-20805 to see if it can safely reduce the number of swelling attacks in adults with hereditary angioedema (HAE). Researchers will measure how much the monthly attack rate decreases over about 6 months of treatment. The trial …
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Phase: PHASE2 • Sponsor: Shanghai Argo Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New daily pill aims to stop dangerous swelling attacks
Disease control OngoingThis study is testing whether a new daily pill called deucrictibant can safely prevent the sudden, painful swelling attacks caused by hereditary angioedema (HAE). About 81 adolescents and adults with HAE will take either the real pill or a placebo (a dummy pill) for 24 weeks to s…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Phase: PHASE3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Disease control
Last updated Mar 10, 2026 12:53 UTC
-
New pill aims to stop dangerous swelling attacks
Symptom relief ENROLLING_BY_INVITATIONThis study is testing the long-term safety and effectiveness of an oral medication called deucrictibant for treating sudden swelling attacks in people with hereditary angioedema (HAE). It will enroll about 150 adults and adolescents who have HAE and have participated in related s…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Phase: PHASE2, PHASE3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Symptom relief
Last updated Mar 20, 2026 14:48 UTC